Europe RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) Geography
Market Introduction
RNA interference (RNAi) is a vital biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. RNAi is an essential research tool in cell culture and living organisms because synthetic dsRNA introduced into cells can induce the suppression of specific genes of interest. RNAi may be used for large-scale screens that orderly shutdown each gene in the cell, which can help to know the components necessary for a particular cellular event such as cell division. The pathway is also used as a practical tool in medicine, biotechnology, and insecticides.
Get more information on this report :
Market Overview and Dynamics
The Europe RNAi therapeutics market is expected to reach US$ 324.33 million in 2027 from US$ 170.42 million in 2019. The market is anticipated to grow at a CAGR of 8.4% during 2019–2027. The growth of the market is attributed to some key driving factors such as growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions. However, high cost of RNAi therapy development is expected to obstruct the growth of the market to a certain extent during the forecast years.
Key Market Segments
In terms of molecule type, the small interfering RNAs (siRNA) segment accounted for the largest share of the Europe RNAi therapeutics market in 2019. In terms of route of administration, the pulmonary delivery segment accounted for the largest share of the Europe RNAi therapeutics market in 2019. In terms of application, oncology segment accounted for the largest share of the Europe RNAi therapeutics market in 2019. In terms of end user, research and academic laboratories segment accounted for the largest share of the Europe RNAi therapeutics market in 2019
Major Sources and Companies Listed
Several major primary and secondary sources associated with the Europe RNAi therapeutics market report are the World Health Organization (WHO), British Lung Foundation, Cancer Research UK, International Trade Administration (ITA), European Federation of Pharmaceutical Industries and Associations (EFPIA) and others.
Reasons to buy report
- It provides understanding of the Europe, RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Europe RNAi therapeutics market.
- It helps efficiently plan merger and acquisition, and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of RNAi therapeutics market performance of various segments pertaining to the Europe RNAi therapeutics market.
- It provides RNAi therapeutics market revenue forecast of the market based on various segments for the period from 2019 to 2027.
EUROPE RNAI THERAPEUTICS MARKET SEGMENTATION
By Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
By Country
- Germany
- UK
- France
- Italy
- Spain
Company Profiles
- Sanofi
- GlaxoSmithKline plc
- Silence Therapeutics
- Alnylam Pharmaceuticals, Inc
- Arrowhead Pharmaceuticals, Inc
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe RNAi Therapeutics Market – By Molecule Type
1.3.2 Europe RNAi Therapeutics Market – By Application
1.3.3 Europe RNAi Therapeutics Market – By Route of Administration
1.3.4 Europe RNAi Therapeutics Market– By End User
1.3.5 Europe RNAi Therapeutics Market – By Country
2. Europe RNAi Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe RNAi Therapeutics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 RNAi therapeutics Market - Europe PEST Analysis
4.3 Expert Opinion
5. Europe RNAi Therapeutics Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Growing Investments in RNAi Therapies
5.1.2 Rising Prevalence of Chronic Conditions and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost for RNAi Therapy Development
5.3 Market Opportunities
5.3.1 Significant Number of Pipeline Candidates for Strategic Alliances
5.4 Future Trends
5.4.1 Rising Emphasis on RNA Technologies
5.5 Impact analysis
6. RNAi Therapeutics Market – Europe Analysis
6.1 Europe RNAi Therapeutics Market Revenue Forecasts and Analysis
7. Europe RNAi Therapeutics Market Analysis and Forecasts To 2027 – By Molecule Type
7.1 Overview
7.2 Europe RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
7.2.1 Europe RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)
7.3 Small Interfering RNAs (siRNA)
7.3.1 Overview
7.3.2 Europe Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)
7.4 MicroRNA (miRNA)
7.4.1 Overview
7.4.2 Europe MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe RNAi therapeutics Market Analysis and Forecasts To 2027 – By Application
8.1 Overview
8.2 Europe RNAi therapeutics Market, By Application 2019 & 2027 (%)
8.2.1 Europe RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Genetic Disorders
8.3.1 Overview
8.3.2 Europe Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Oncology
8.4.1 Overview
8.4.2 Europe Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Neurodegenerative Disorders
8.5.1 Overview
8.5.2 Europe Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Cardiovascular Disorders
8.6.1 Overview
8.6.2 Europe Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Europe Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Infectious Diseases
8.8.1 Overview
8.8.2 Europe Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.9 Renal Diseases
8.9.1 Overview
8.9.2 Europe Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
8.10 Other Disorders
8.10.1 Overview
8.10.2 Europe Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
9. Europe RNAi therapeutics Market Analysis and Forecasts To 2027 – By Route of Administration
9.1 Overview
9.2 Europe RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
9.2.1 Europe RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
9.3 Intradermal Injections
9.3.1 Overview
9.3.2 Europe Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Pulmonary Delivery
9.4.1 Overview
9.4.2 Europe Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Intravenous Injections
9.5.1 Overview
9.5.2 Europe Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Intraperitoneal Injections
9.6.1 Overview
9.6.2 Europe Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Other Route of Administrations
9.7.1 Overview
9.7.2 Europe Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Europe RNAi Therapeutics Market Analysis – By End-User
10.1 Overview
10.2 Europe RNAi Therapeutics Market, By End-User 2019-2027 (%)
10.2.1 Europe RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)
10.3 Diagnostic Laboratories
10.3.1 Overview
10.3.2 Europe Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Research and Academic Laboratories
10.4.1 Overview
10.4.2 Europe Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Hospitals
10.5.1 Overview
10.5.2 Europe Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
11. RNAi therapeutics Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 Europe: RNAi Therapeutics Market
11.1.1 Overview
11.1.2 Europe: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.4 Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.5 Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.6 Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.7 Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
11.1.8 Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.8.3 Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.8.4 Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.8.5 Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.9 UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 UK RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.9.3 UK RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.9.4 UK RNAi Therapeutics Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
11.1.9.5 UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)
11.1.10 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.10.3 France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.10.4 France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.10.5 France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.11 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.1 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.2 Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.11.3 Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.11.4 Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.11.5 Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.1.12 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.1 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.2 Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
11.1.12.3 Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.12.4 Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.12.5 Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
12. Impact of COVID-19 Pandemic on Europe RNAi therapeutics Market
12.1 Europe: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)
Table 2. Europe RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. Europe RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 4. Europe RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)
Table 5. Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 6. Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 7. Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 8. Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 9. Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 10. Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 11. Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 13. United Kingdom RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 14. United Kingdom RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. UK: RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million).
Table 16. UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)
Table 17. France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 18. France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 19. France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 20. France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 21. Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 22. Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 23. Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 24. Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 25. Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)
Table 26. Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 27. Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 28. Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 29. Glossary of Terms, RNAi Therapeutics Market
LIST OF FIGURES
Figure 1. RNAi Therapeutics Market Segmentation
Figure 2. Europe RNAi Therapeutics Market Overview
Figure 3. Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market
Figure 4. UK is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Europe RNAi Therapeutics Market - Leading Country Markets (US$ Mn)
Figure 6. RNAi Therapeutics Market - Europe PEST Analysis
Figure 7. RNAi Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Europe RNAi Therapeutics Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Europe RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)
Figure 10. Europe Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Europe MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Europe RNAi therapeutics Market, By Application 2019 & 2027 (%)
Figure 13. Europe Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Europe Oncology Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Europe Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Europe Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Europe Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Europe Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Europe Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Europe Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Europe RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)
Figure 22. Europe Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Europe Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Europe Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Europe Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Europe Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Europe RNAi Therapeutics Market, by End-User 2019 & 2027 (%)
Figure 28. Europe Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Europe Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. Europe Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 31. Europe: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 32. Europe RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)
Figure 33. Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 34. Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 39. Impact of COVID-19 Pandemic in Europe Country Markets
- Sanofi
- GlaxoSmithKline plc
- Silence Therapeutics
- Alnylam Pharmaceuticals, Inc
- Arrowhead Pharmaceuticals, Inc
- It provides understanding of the Europe, RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Europe RNAi therapeutics market.
- It helps efficiently plan merger and acquisition, and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of RNAi therapeutics market performance of various segments pertaining to the Europe RNAi therapeutics market.
- It provides RNAi therapeutics market revenue forecast of the market based on various segments for the period from 2019 to 2027.